Concepedia

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

Paul Dorian, Thitima Kongnakorn, Hemant Phatak, Dale Rublee, Andreas Kuznik, Tereza Lanitis, Liu Lz, U Iloeje, Luis Hernández, Gregory Y.H. Lip

European Heart Journal · 2014 · 94 citations · 29 references

DOIFull text

Open access

Abstract

Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively.

References

29

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Scott M. Grundy · JAMA · 1993 · 27.9K citations

, , +12

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

Evaluation Expert Panel on Detection · JAMA · 2001 · 25.8K citations

, , +16

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Christopher B. Granger, John H. Alexander, John J.V. McMurray et al. · New England Journal of Medicine · 2011 · 8.8K citations · Full text

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

EP Europace · 2012 · 3.8K citations · Full text

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

European Heart Journal · 2012 · 2.9K citations